[go: up one dir, main page]

MX2016004267A - Combinacion. - Google Patents

Combinacion.

Info

Publication number
MX2016004267A
MX2016004267A MX2016004267A MX2016004267A MX2016004267A MX 2016004267 A MX2016004267 A MX 2016004267A MX 2016004267 A MX2016004267 A MX 2016004267A MX 2016004267 A MX2016004267 A MX 2016004267A MX 2016004267 A MX2016004267 A MX 2016004267A
Authority
MX
Mexico
Prior art keywords
hydroxylase
chloro
inhibition
methyl
pharmaceutically acceptable
Prior art date
Application number
MX2016004267A
Other languages
English (en)
Inventor
Rakesh Kumar
Mark J Cornfeld
Shannon Renae Morris
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016004267A publication Critical patent/MX2016004267A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una nueva combinación que comprende un inhibidor de la 17 a-hidroxilasa/C17,20 liasa, por ejemplo: (3ß)-17-(piridin-3-il)and rosta-5,16-dien-3-ol o una sal o ester farmacéuticamente aceptable del mismo, y un compuesto inhibidor de AKT, por ejemplo: N-{(1S)-2-amino-1-[(3,4-difluorofenil)metil]etil}-5-cloro -4-(4-cloro-1-metil-1H-pirazol-5-iI)-2-tiofenocarboxamida o una sal farmacéuticamente aceptable del mismo, y agentes antineoplásicos adicionales opcionales; composiciones farmacéuticas que comprenden los mismos y métodos de uso de tales combinaciones y composiciones en el tratamiento de condiciones en las que la inhibición de la 17 a-hidroxilasa/C17,20 liasa y/o la inhibición de AKT es beneficiosa, por ejemplo, cáncer.
MX2016004267A 2013-10-01 2014-10-01 Combinacion. MX2016004267A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361885049P 2013-10-01 2013-10-01
US201461933379P 2014-01-30 2014-01-30
PCT/IB2014/064996 WO2015049649A1 (en) 2013-10-01 2014-10-01 Combination

Publications (1)

Publication Number Publication Date
MX2016004267A true MX2016004267A (es) 2016-07-08

Family

ID=51830565

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004267A MX2016004267A (es) 2013-10-01 2014-10-01 Combinacion.

Country Status (11)

Country Link
US (5) US20160228456A1 (es)
EP (3) EP3052097A1 (es)
JP (3) JP2016531884A (es)
KR (1) KR20160065910A (es)
CN (3) CN109806266A (es)
AU (2) AU2014330779A1 (es)
BR (1) BR112016006976A2 (es)
CA (1) CA2925374A1 (es)
MX (1) MX2016004267A (es)
RU (1) RU2016116915A (es)
WO (1) WO2015049649A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020180942A1 (en) 2019-03-06 2020-09-10 Propella Therapeutics, Inc. Abiraterone prodrugs
CA3148115A1 (en) * 2019-08-08 2021-02-11 Laekna Limited Method of treating cancer
EP4284378A4 (en) * 2021-02-01 2024-12-25 Taiho Pharmaceutical Co., Ltd. Ptentreating cancer in patient with pten inactivating mutation
EP4493189A1 (en) 2022-03-14 2025-01-22 Laekna Limited Combination treatment for cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
CA2167526A1 (en) * 1993-09-29 1995-04-06 Lina Tormen Taskovich Monoglyceride/lactate ester permeation enhancer
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
DE19918106A1 (de) * 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
DE10107663B4 (de) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
CN101528308A (zh) * 2006-08-25 2009-09-09 库伽尔生物科技公司 治疗癌症的方法和组合物
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ES2522365T3 (es) * 2007-10-11 2014-11-14 Astrazeneca Ab Derivados de pirrolo [2,3-D] pirimidina como inhibidores de proteína quinasas B
CN102405047B (zh) 2009-01-30 2014-07-09 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
NZ596488A (en) * 2009-06-26 2012-11-30 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
JP5586888B2 (ja) * 2009-07-23 2014-09-10 帝國製薬株式会社 非含水貼付製剤
JP5222916B2 (ja) * 2010-09-17 2013-06-26 シャープ株式会社 半導体基材の製造方法、半導体装置、および電気機器
SG10201600077RA (en) * 2011-01-11 2016-02-26 Glaxosmithkline Llc Combination
EP2694072B2 (en) * 2011-04-01 2024-08-07 Genentech, Inc. Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
DK2785349T4 (da) * 2011-11-30 2023-01-09 Astrazeneca Ab Kombinationsbehandling af cancer
CN103301093B (zh) * 2013-06-03 2015-10-21 华润紫竹药业有限公司 睾酮透皮吸收贴剂

Also Published As

Publication number Publication date
WO2015049649A1 (en) 2015-04-09
US20250017947A1 (en) 2025-01-16
EP4265300A2 (en) 2023-10-25
JP2019218357A (ja) 2019-12-26
RU2016116915A3 (es) 2018-05-28
US20200222431A1 (en) 2020-07-16
EP3052097A1 (en) 2016-08-10
JP6907273B2 (ja) 2021-07-21
AU2014330779A1 (en) 2016-04-07
CN109806266A (zh) 2019-05-28
CA2925374A1 (en) 2015-04-09
JP7235807B2 (ja) 2023-03-08
US20170239274A1 (en) 2017-08-24
AU2017228673A1 (en) 2017-10-05
JP2016531884A (ja) 2016-10-13
CN105792825A (zh) 2016-07-20
BR112016006976A2 (pt) 2017-08-01
KR20160065910A (ko) 2016-06-09
JP2021155446A (ja) 2021-10-07
EP4265300A3 (en) 2023-11-29
EP4265300B1 (en) 2025-12-10
US20160228456A1 (en) 2016-08-11
US20180264008A1 (en) 2018-09-20
RU2016116915A (ru) 2017-11-13
CN109674801A (zh) 2019-04-26
EP3718544A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX378315B (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
PH12016500024A1 (en) Bromodomain inhibitor
NZ728072A (en) Modulators of toll-like receptors for the treatment of hiv
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
UY36121A (es) ?pirazolopiridinas y pirazolopirimidinas?.
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MY183974A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
MY162397A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
AR094553A1 (es) Formas de oxadiazolpirazina
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
EA201791807A1 (ru) Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич
CL2012003006A1 (es) Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer.